Company intelligence / Profile preview

AccuStem Sciences

New York, New York, United Statesaccustem.com ↗

Ownership: Private
Employees: ~2
Development stage: Preclinical

Overview

AccuStem is developing proprietary genomic and molecular diagnostic tests for oncology. Its lead program, the MSC test—a 24-microRNA assay—aims to distinguish benign from malignant lung nodules found on low-dose CT scans. Another key product is StemPrintER, a gene expression-based prognostic tool for predicting distant recurrence in luminal breast cancer patients. The company is currently pre-commercial with plans to launch its first product in early 2026

Therapeutic areas: Oncology
Modalities: Genomic testMolecular diagnosticsMicroRNA assay (for MSC test)Gene expression assay (for StemPrintER)
Industry: Molecular Diagnostics

Partnerships

EmeritusDX – partnership announced April 28, 2025, to commercialize the MSC Test for lung cancer screening

Beyond the preview

Go deeper on AccuStem Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AccuStem Sciences.

Explore the full profile